sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

P&G Announces Fourth Quarter and Fiscal Year 2026 Results

View original at finance.yahoo.com
P&G Announces Fourth Quarter and Fiscal Year 2026 Results Q4 '26: Net Sales +2%; Organic Sales 0%; Diluted EPS -15%; Core EPS -3% FY '26: Net Sales +3%; Organic Sales +1%; Diluted EPS +2%; Core EPS +1% CINCINNATI, July 29, 2026--(BUSINESS WIRE)--The Procter & Gamble Company (NYSE:PG) reported fourth quarter and fiscal…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fiscal 2026 was a year of foundation building while continuing to grow sales and profit and return high levels of cash to shareowners despite a very challenging geopolitical and economic environment; expects progress in fiscal 2027 by doubling down on strategy, prioritizing the consumer, and funding investments with a strong productivity program.

    60% confidence

Data points we hold from this source

Procter & Gamble · core eps6.89 USD
Procter & Gamble · adjusted free cash flow productivity100 percent
Procter & Gamble · organic sales growth0 percent
Procter & Gamble · operating cash flow19.6 USD
Procter & Gamble · net income16.1 USD
Procter & Gamble · eps6.62 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com